Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
THURSDAY, Sept. 24, 2020 -- For individuals with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors are associated with a reduced risk for cardiovascular events during short-term follow-up, according to a study published online Sept....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Pharmaceuticals | SGLT2 Inhibitors | Sodium | Study